Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma.
We suggest that surveillance for squamous cell cancer might be particularly useful for transplant patients receiving statin therapy. We recommend that development of non melanoma skin cancer should be specified as a secondary endpoint in future large endpoint statin trials, and suggest that in transplant patients the adverse effects of statin drugs may outweigh benefits, especially in women and the elderly, a subset of population in which even individuals at high risk for cardiovascular disease have shown no trend to net benefit from statins.
Mascitelli
Luca
L
Comando Brigata Alpina Julia, Medical Service, 8 Via S. Agostino, Udine, 33100, Italy. lumasci@libero.it
Pezzetta
Francesca
F
Goldstein
Mark R
MR
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology*; D002986:Clinical Trials as Topic; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D016377:Organ Transplantation; D018570:Risk Assessment; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors